Antiepileptic drugs in the elderly: The place of gabapentin

Reviews in Contemporary Pharmacotherapy

Volumn 7, Issue 5, 1996, Pages 227-232

  Walker, M C ^a   Sander, J W A S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005927166     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ashmark H, Wilholm BE. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 1990; 81: 131-140.
2. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982; 31: 301-304.
3. Bauer LA, Davis R, Wilensky A, Raisys V, Levy RH. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther 1985; 37: 697-700.
4. Blum MR, Riegelman S, Becker CE. Altered protein binding of diphenylhydantoin in uremic plasma. N Engl J Med 1972; 286: 109.
5. Blum RA, Comstock TJ, Sica DA et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994; 56: 154-159.
6. Busch JA, Radulovic LL, Bockbader HN, Underwood BA, Sedman AJ, Chang T. Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy subjects. Pharm Res 1992; 9 (Suppl 10): 315.
7. Cadieux RJ. Drug interactions in the elderly. Postgrad Med 1989; 86: 179-186.
8. Castleden CM, George CF, Marcer D, Hallett C. Increased sensitivity to nitrazepam in old age. Br Med J 1977; 1: 10-12.
9. Chadwick D. Gabepentin: clinical use. In: Levy RH, Mattson RH, Meldrum BS, eds. Antieptileptic drugs. Fourth Edn. New York: Raven Press, 1995: 851-856.
10. Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. Arch Fam Med 1994; 3: 589-598.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
12. Cockerell OC, Eckle I, Goodridge DMG, Sander JWAS, Shorvon SD. Epilepsy in a population of 6000 re-examined: secular trends in first attendance rates, prevalence, and prognosis. Lancet 1995a; 58: 570-576.
13. Cockerell OC, Johnson AL, Sander JWAS, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995b; 346: 140-144.
14. Cohen J, Scheuer ML. Antiepileptic drug use in elderly patients with epilepsy. Epilepsia 1991; 32 (Suppl 3): 53.
15. Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994; 35: 381-390.
16. Fraser DG, Ludden TM, Evens RP, Sutherland EW. Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther 1980; 27: 165-169.
17. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34: 453-468.
18. Kenneback G, Bergfeldt L, Tomson T, Spina E, Edhag O. Carbamazepine induced bradycardia - a problem in general or only in susceptible patients? A 24-h long-term electrocardiogram study. Epilepsy Res 1992; 13: 141-145.
19. Tallis R, Hall G, Craig I, Dean A. How common are epileptic seizures in old age? Age Ageing 1991; 20: 442-448.
20. Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 1995; 67: 351-384.
21. Walker MC, Patsalos PN. The tolerability and safety profile of gabapentin. Rev Contemp Pharmacother 1996; 7: 249-257.
22. Walker MC, Sander JWAS. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 1996; 46: 912-914.